Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SucrAlphate
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Recipient : Clayton Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval of Sucralfate Oral Suspension, through initial development of twelve different bioassays that tracked product's postulated clinical interactions using in vitro biology, marks a paradigm shift in how complex generic drug products can be comme...
Product Name : Sucralfate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2022
Lead Product(s) : SucrAlphate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : Clayton Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable